GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IN MYOCARDIAL INFARCTION AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK REDUCTION: A COMPREHENSIVE META-ANALYSIS OF NUMBER NEEDED TO TREAT, EFFICACY AND SAFETY